<DOC>
	<DOCNO>NCT02437162</DOCNO>
	<brief_summary>The purpose study assess efficacy ustekinumab , adult participant active radiographic axial spondyloarthritis ( AxSpA ) , naive anti-TNF alpha agent , measure reduction sign symptom radiographic AxSpA .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Ustekinumab Treatment Anti-TNFÎ± Naive Participants With Active Radiographic Axial Spondyloarthritis</brief_title>
	<detailed_description>This Phase 3 , multicenter ( one hospital medical school team work medical research study ) , randomize ( study medication assign participant chance ) , double-blind ( neither researcher participant know treatment participant receiving ) , placebo-controlled ( inactive substance ; pretend treatment [ drug ] compare clinical trial drug test drug real effect ) study . The study consist 3 phase ; Screening ( 8 week ) , Treatment phase : placebo-controlled ( Week 0 24 ) active treatment ( Week 24 Week 100 ) , Safety Follow-up ( 12 week last dose ) . Participants randomly assign 1 3 treatment group : placebo , ustekinumab 45 mg ustekinumab 90 mg . The total duration study 112 week . Participants primarily assess Assessment SpondyloArthritis International Society ( ASAS ) 40 response Week 24 . Participants ' safety monitor throughout trial .</detailed_description>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participants must diagnosis definite ankylose spondylitis ( AS ) , define modified 1984 New York criterion . The radiographic criterion must confirm central xray reader least 1 clinical criterion must meet Participants must symptoms active disease screen baseline , evidence BASDAI score great equal ( &gt; =4 ) visual analog scale ( VAS ) score total back pain &gt; =4 , scale 0 10 Participants elevate high sensitivity Creactive protein ( hsCRP ) level &gt; =0.300 milligram per deciliter ( mg/dL ) Screening If use nonsteroidal antiinflammatory drug ( NSAIDs ) analgesic AS , must stable dose least 2 week prior first administration study agent . If currently use NSAIDs analgesic AS , must receive NSAIDs analgesic AS least 2 week prior first administration study agent A woman childbearing potential must negative serum ( betahuman chorionic gonadotropin [ betahCG ] ) screen negative urine pregnancy test Week 0 randomization Participants inflammatory disease might confound evaluation benefit ustekinumab therapy , include limited , rheumatoid arthritis , systemic lupus erythematosus , Lyme disease Participants pregnant , nursing , plan pregnancy father child enrol study within 5 month receive last administration study agent Participants receive prior biologic therapy , include limited antiTNF alpha agent , tocilizumab , alefacept , efalizumab , natalizumab , abatacept , anakinra , ustekinumab , tidrakizumab antiinterleukin ( IL ) 23 biologics , brodalumab , secukinumab , ixekizumab , Bcell deplete therapy Participants receive systemic immunosuppressive diseasemodifying antirheumatic drug ( DMARDs ) methotrexate ( MTX ) , sulfasalazine ( SSZ ) , hydroxychloroquine ( HCQ ) within 4 week prior first administration study agent . Medications category include , limited chloroquine , azathioprine , cyclosporine , mycophenolate mofetil , gold , penicillamine Participant receive leflunomide within 3 month prior first administration study agent ( irrespective undergoing drug elimination procedure ) , receive leflunomide within 12 month prior first administration study agent undergone drug elimination procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Axial Spondyloarthritis</keyword>
	<keyword>Ustekinumab</keyword>
	<keyword>Golimumab</keyword>
	<keyword>Stelara</keyword>
</DOC>